BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/301935% above fair value
$416.54+0.58 (+0.14%)
Close on Nov 13, 2026Market cap $47.36BP/E 53.4Yield –
BeOne Medicines r&d expenses
Research and development expenses are spending on new products and technology.
BeOne Medicines's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.43B, up 17.2% year over year. For fiscal 2025 it was $2.15B, up 9.9% from the year before. Over ten years it grew 43.4% a year on average. The highest annual figure on record is $2.15B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.15B | +9.9% |
| FY2024 | Dec 31, 2024 | $1.95B | +9.8% |
| FY2023 | Dec 31, 2023 | $1.78B | +8.4% |
| FY2022 | Dec 31, 2022 | $1.64B | +12.4% |
| FY2021 | Dec 31, 2021 | $1.46B | +12.7% |
| FY2020 | Dec 31, 2020 | $1.29B | +39.6% |
| FY2019 | Dec 31, 2019 | $927.34M | +36.6% |
| FY2018 | Dec 31, 2018 | $679.01M | +152.4% |
| FY2017 | Dec 31, 2017 | $269.02M | +174.4% |
| FY2016 | Dec 31, 2016 | $98.03M | +68.3% |
| FY2015 | Dec 31, 2015 | $58.25M | +166.4% |
| FY2014 | Dec 31, 2014 | $21.86M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $660.78M | +26.2% |
| Q2 FY2026 | Jun 30, 2026 | $612.28M | +16.6% |
| Q1 FY2026 | Mar 31, 2026 | $541.22M | +12.3% |
| Q4 FY2025 | Dec 31, 2025 | $615.42M | +13.5% |
| Q3 FY2025 | Sep 30, 2025 | $523.66M | +5.5% |
| Q2 FY2025 | Jun 30, 2025 | $524.90M | +15.5% |
| Q1 FY2025 | Mar 31, 2025 | $481.89M | +4.6% |
| Q4 FY2024 | Dec 31, 2024 | $542.01M | +9.7% |
| Q3 FY2024 | Sep 30, 2024 | $496.18M | +9.5% |
| Q2 FY2024 | Jun 30, 2024 | $454.47M | +7.5% |
| Q1 FY2024 | Mar 31, 2024 | $460.64M | +12.7% |
| Q4 FY2023 | Dec 31, 2023 | $493.99M | +10.8% |
| Q3 FY2023 | Sep 30, 2023 | $453.26M | +6.3% |
| Q2 FY2023 | Jun 30, 2023 | $422.76M | +11.8% |
| Q1 FY2023 | Mar 31, 2023 | $408.58M | +4.8% |
| Q4 FY2022 | Dec 31, 2022 | $446.02M | +3.6% |
| Q3 FY2022 | Sep 30, 2022 | $426.36M | +21.1% |
| Q2 FY2022 | Jun 30, 2022 | $378.21M | +6.2% |
| Q1 FY2022 | Mar 31, 2022 | $389.92M | +21.6% |
| Q4 FY2021 | Dec 31, 2021 | $430.49M | +21.1% |
| Q3 FY2021 | Sep 30, 2021 | $351.94M | +0.8% |
| Q2 FY2021 | Jun 30, 2021 | $356.09M | +24.5% |
| Q1 FY2021 | Mar 31, 2021 | $320.73M | +5.4% |
| Q4 FY2020 | Dec 31, 2020 | $355.54M | +25.5% |
| Q3 FY2020 | Sep 30, 2020 | $349.07M | +47.3% |
| Q2 FY2020 | Jun 30, 2020 | $285.97M | +25.0% |
| Q1 FY2020 | Mar 31, 2020 | $304.30M | +70.6% |
| Q4 FY2019 | Dec 31, 2019 | $283.26M | +10.0% |
| Q3 FY2019 | Sep 30, 2019 | $236.97M | +60.6% |
| Q2 FY2019 | Jun 30, 2019 | $228.76M | +39.3% |
| Q1 FY2019 | Mar 31, 2019 | $178.35M | +62.6% |
| Q4 FY2018 | Dec 31, 2018 | $257.46M | +181.9% |
| Q3 FY2018 | Sep 30, 2018 | $147.59M | +68.4% |
| Q2 FY2018 | Jun 30, 2018 | $164.25M | +247.7% |
| Q1 FY2018 | Mar 31, 2018 | $109.70M | +156.5% |
| Q4 FY2017 | Dec 31, 2017 | $91.34M | +215.7% |
| Q3 FY2017 | Sep 30, 2017 | $87.66M | – |
| Q2 FY2017 | Jun 30, 2017 | $47.25M | – |
| Q1 FY2017 | Mar 31, 2017 | $42.77M | – |
| Q4 FY2016 | Dec 31, 2016 | $28.93M | – |
See a number that looks wrong?